The effect of the oral and intravenous administration of the dihydrogenated ergot alkaloids on 25 cases of essential hypertension in the age group of 25 to 56 is reported with reference to (1) incidence of hypotensive effect, (2) degree of hypotensive effect, (3) duration of the hypotensive effect.
The effect of the oral and intravenous administration of the dihydrogenated ergot alkaloids on 25 cases of essential hypertension in the age group of 25 to 56 is reported with reference to (1) incidence of hypotensive effect, (2) degree of hypotensive effect, (3) duration of the hypotensive effect.
ANEW preparation, C.C.K.-179, a combination of equal amounts of dihydroergocristine, dihydroergokryptine, and dihydroergocornine, has recently been used in the treatment of hypertension. The 285 not only lower blood pressure but must arrest or reverse the progressive pathologic lesions of the vascular tree. These lesions are far more significant than the height of the blood pressure and do not necessarily parallel blood pressure elevation. The best presently available objective means of detecting a therapeutic response in essential hypertension is probably a serial determination of the blood pressure and eye ground studies with an adequate pre-and post-therapy control period; at least, until the basic etiologic factors of essential hypertension are definitely known.
The 25 patients to whom we gave a trial on oral C.C.K.-179 have been followed by us, on an ambulatory basis, at frequent intervals for a period of 18 to 36 months. Most were seen in a special hypertension clinic. We are acquainted with the social and economic status of these patients, and with the individual variations of the blood pressure of each. DIHYDROGENATED ERGOT ALKALOIDS which were gradually increased. The average maximum daily dose was 7.5 mg. in tablet form and 5.6 mg. in liquid form. The daily maximum dose was maintained for a minimum of one week. The extremes of daily dosage (tablets) were 3 mg. and 10 mg.; and (liquid) 2 mg. and 10.6 mg. Therapy was continued for from three weeks to three months. Alarming side effects were not encountered, probably because the dosage was not pushed to serious individual toxicity. Nevertheless, four patients had mild nausea, two had dizziness, and three experienced drowsiness. Because of these effects, several patients requested that the drug be discontinued.
One patient showed a significant blood pressure drop from 228/140 to 198/110 with a concomitant alleviation of headache. On discontinuing the drug the blood pressure slowly rose to pretreatment levels. This drop occurred on a dosage level of 8 to 9 mg. daily. 
CONCLUSION
We do not doubt that the dihydrogenated ergot alkaloid preparations are capable of lowering blood pressure when given in sufficiently large doses, intravenously and orally. However, from a clinical standpoint we do not feel that the particular compounds we used have any practical application in the management of an individual with essential hypertension because of (1) the extreme low incidence of hypotensive effect;
(2) the minimal degree of hypotensive effect when this result was obtained; and (3) the short duration of the hypotensive effect of the intravenous form of the compound.
